Yvonne Yingwai Cheung, MD | |
30 Clark St, Belmont, MA 02478-2451 | |
(617) 489-2499 | |
Not Available |
Full Name | Yvonne Yingwai Cheung |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 30 Clark St, Belmont, Massachusetts |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1871574160 | NPI | - | NPPES |
3148114 | Other | MA | MASS HEALTH |
J31742 | Other | MA | BLUE SHIELD |
754180 | Other | MA | TUFTS |
050081612 | Other | MA | TRAVELERS/RAILROAD MEDICA |
275008 | Other | MA | HARVARD PILGRIM |
30201737 | Other | MA | NEW HAMPSHIRE MEDICAID |
30490 | Other | MA | CHILDREN'S MEDICAL SECURI |
30490 | Other | MA | HEALTHY START |
30490 | Other | MA | COMMONWEALTH INDEMNITY (G |
YC40954 | Other | MA | RHODE ISLAND MEDICAID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 76527 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Yvonne Yingwai Cheung, MD 30 Clark St, Belmont, MA 02478-2451 Ph: (617) 489-2499 | Yvonne Yingwai Cheung, MD 30 Clark St, Belmont, MA 02478-2451 Ph: (617) 489-2499 |
News Archive
MicroStockProfit.com announces an investment report featuring VIVUS Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.
Nearly one-fourth of cigarette smokers believe that so-called reduced-exposure tobacco products - such as "light," herbal or reduced nicotine cigarettes - are less harmful to their health than conventional cigarettes, a new study finds. However, such beliefs are not backed up by existing evidence, according to the study's authors.
Mayo Clinic researchers have discovered that the five-year survival of diabetic kidney transplant patients is now on par with the five-year survival of nondiabetic kidney recipients.
› Verified 8 days ago